In a prospective study on 423 melanoma patients, Donnelly et al. showed no difference in PFS or OS in the entire cohort, with a positive association in patients treated with a combination of anti-CTLA-4 and anti-PD-1, but not with anti-CTLA-4 or anti-PD-1 alone [147]. This evidence concerns the gene CTLA4 and melanoma.